|
gptkbp:instanceOf
|
gptkb:drug
selective estrogen receptor modulator
|
|
gptkbp:administeredBy
|
gptkb:tablet
oral solution
|
|
gptkbp:approvalYear
|
1977
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L02BA01
|
|
gptkbp:brand
|
gptkb:Nolvadex
gptkb:Soltamox
|
|
gptkbp:CASNumber
|
gptkb:10540-29-1
|
|
gptkbp:category
|
antineoplastic agent
endocrine therapy
hormonal antineoplastic agent
prodrug
|
|
gptkbp:chemicalFormula
|
gptkb:C26H29NO
|
|
gptkbp:contraindication
|
pregnancy
history of deep vein thrombosis
history of pulmonary embolism
|
|
gptkbp:developedBy
|
gptkb:ICI_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:Dora_Richardson
|
|
gptkbp:eliminationHalfLife
|
5-7 days
|
|
gptkbp:foundIn
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tamoxifen
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:SSRIs
CYP2D6 inhibitors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
estrogen receptor agonist in uterus
estrogen receptor antagonist in breast tissue
|
|
gptkbp:metabolism
|
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prodrugFor
|
gptkb:4-hydroxytamoxifen
gptkb:endoxifen
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
increased risk of blood clots
mood changes
hot flashes
increased risk of endometrial cancer
leg cramps
|
|
gptkbp:usedFor
|
gptkb:cancer
infertility
gynecomastia
prevention of breast cancer
treatment of ductal carcinoma in situ
treatment of metastatic breast cancer
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:ICI_Pharmaceuticals
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|